Efficacy and safety of telitacicept in IgA nephropathy: a real-world study
Background IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and huma...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2449580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850082499062923264 |
|---|---|
| author | Lingqiu Dong Dandan Yang Aiya Qin Siqing Wang Yi Tang Jiaxing Tan Wei Qin |
| author_facet | Lingqiu Dong Dandan Yang Aiya Qin Siqing Wang Yi Tang Jiaxing Tan Wei Qin |
| author_sort | Lingqiu Dong |
| collection | DOAJ |
| description | Background IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.Aim To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.Methods Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.Results Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.Conclusion Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile. |
| format | Article |
| id | doaj-art-7b63b07ecf344b43b412e4422cd816ff |
| institution | DOAJ |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-7b63b07ecf344b43b412e4422cd816ff2025-08-20T02:44:31ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492025-12-0147110.1080/0886022X.2025.2449580Efficacy and safety of telitacicept in IgA nephropathy: a real-world studyLingqiu Dong0Dandan Yang1Aiya Qin2Siqing Wang3Yi Tang4Jiaxing Tan5Wei Qin6Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaBackground IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.Aim To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.Methods Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5 g/d who received 240 mg telitacicept weekly were recruited for this study and 1:1:1 matched with patients who received supportive treatment only or immunosuppressive treatment by propensity score matching. The primary outcome was the change from baseline in 24-hour proteinuria over the 3-month follow-up.Results Twenty-one patients in each group were enrolled. Telitacicept reduced median proteinuria by 0.72 g/d (54.6%) from baseline, compared with a reduction of 0.18 g/d (20%) in the supportive treatment group and 1.12 g/d (72.1%) in the immunosuppressive treatment group. Preserved eGFR levels were observed in the telitacicept group, whereas eGFR levels decreased in the other two groups. No serious adverse events were observed in the telitacicept treatment group.Conclusion Telitacicept may be an effective treatment for IgAN patients by reducing proteinuria and preserving eGFR, and showed a favorable safety profile.https://www.tandfonline.com/doi/10.1080/0886022X.2025.2449580IgA nephropathytelitaciceptproteinuriaBLyS/APRIL inhibitorskidney function |
| spellingShingle | Lingqiu Dong Dandan Yang Aiya Qin Siqing Wang Yi Tang Jiaxing Tan Wei Qin Efficacy and safety of telitacicept in IgA nephropathy: a real-world study Renal Failure IgA nephropathy telitacicept proteinuria BLyS/APRIL inhibitors kidney function |
| title | Efficacy and safety of telitacicept in IgA nephropathy: a real-world study |
| title_full | Efficacy and safety of telitacicept in IgA nephropathy: a real-world study |
| title_fullStr | Efficacy and safety of telitacicept in IgA nephropathy: a real-world study |
| title_full_unstemmed | Efficacy and safety of telitacicept in IgA nephropathy: a real-world study |
| title_short | Efficacy and safety of telitacicept in IgA nephropathy: a real-world study |
| title_sort | efficacy and safety of telitacicept in iga nephropathy a real world study |
| topic | IgA nephropathy telitacicept proteinuria BLyS/APRIL inhibitors kidney function |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2449580 |
| work_keys_str_mv | AT lingqiudong efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT dandanyang efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT aiyaqin efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT siqingwang efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT yitang efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT jiaxingtan efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy AT weiqin efficacyandsafetyoftelitaciceptiniganephropathyarealworldstudy |